AI Insight
A phase 2 clinical trial evaluated zenagamtide, a once-weekly injectable medication that combines GLP-1 and amylin receptor agonist properties, in patients with type 2 diabetes. The study found that doses ranging from 0.4 to 40 mg produced statistically significant reductions in HbA1c levels (a key measure of blood sugar control) compared to placebo over 36 weeks. The medication's side effects were consistent with other drugs in the GLP-1 and amylin therapeutic classes.
Why it matters
This dual-action medication could offer a more convenient treatment option for type 2 diabetes patients, requiring only weekly injections rather than daily medication. The combination mechanism may provide improved glycemic control, though larger phase 3 trials are needed to confirm efficacy and long-term safety before potential clinical use.
Understand the Science
In people with type 2 diabetes, once-weekly subcutaneous zenagamtide 0·4–40 mg demonstrated clinically meaningful and significant improvements in change in HbA1c from baseline to week 36 compared with placebo, with a safety and tolerability profile consistent with that of other GLP-1-based and amylin-based therapies.